Non-responder migraine patients to a first anti-CGRP monoclonal antibody benefit from a switch to a second one.
作者信息
Fresán-Restituto D, Lacalle-Fabo E, Martín-Bujanda M, Sarobe-Carricas M T
机构信息
Hospital Universitario de Navarra, Pamplona, España.
出版信息
Rev Neurol. 2023 Mar 16;76(6):213-216. doi: 10.33588/rn.7606.2022350.
Abstract
摘要
相似文献
1
Non-responder migraine patients to a first anti-CGRP monoclonal antibody benefit from a switch to a second one.对第一种抗降钙素基因相关肽（CGRP）单克隆抗体无反应的偏头痛患者换用第二种该类药物会从中获益。
Rev Neurol. 2023 Mar 16;76(6):213-216. doi: 10.33588/rn.7606.2022350.
2
Galcanezumab for the prevention of migraine.加巴喷丁预防偏头痛。
Pain Manag. 2021 Mar;11(2):101-112. doi: 10.2217/pmt-2020-0030. Epub 2020 Dec 9.
3
Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.在多次评估的无反应患者中更换抗降钙素基因相关肽（CGRP）单克隆抗体及其对无效标准的影响：一项回顾性队列研究
Cephalalgia. 2023 Apr;43(4):3331024231160519. doi: 10.1177/03331024231160519.
4
Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study.从靶向 CGRP 通路的另一种 mAb 转换为依洛尤单抗治疗偏头痛患者的真实世界疗效：Finesse 研究的亚组分析。
J Headache Pain. 2023 May 23;24(1):59. doi: 10.1186/s10194-023-01593-2.
5
Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.在实践中 3 种 CGRP 单克隆抗体的安全性和耐受性：一项回顾性队列研究。
Headache. 2020 Nov;60(10):2454-2462. doi: 10.1111/head.13956. Epub 2020 Sep 23.
6
CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine.降钙素基因相关肽单克隆抗体用于偏头痛的预防性治疗。
Curr Pain Headache Rep. 2018 Apr 6;22(5):38. doi: 10.1007/s11916-018-0686-4.
7
Genetic variants associated with response to anti-CGRP monoclonal antibody therapy in a chronic migraine Han Chinese population.与慢性偏头痛汉族人群中抗 CGRP 单克隆抗体治疗反应相关的遗传变异。
J Headache Pain. 2024 Sep 12;25(1):149. doi: 10.1186/s10194-024-01850-y.
8
Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series.针对 CGRP（R）的单克隆抗体：无应答者和转换者：来自奥地利病例系列的真实世界数据。
BMC Neurol. 2023 Apr 28;23(1):174. doi: 10.1186/s12883-023-03203-9.
9
History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.降钙素基因相关肽（CGRP）拮抗剂治疗的历史和综述：从转化研究到治疗。
Headache. 2018 Nov;58 Suppl 3:238-275. doi: 10.1111/head.13379. Epub 2018 Sep 22.
10
[Novel migraine treatment with CGRP-related monoclonal antibodies].[使用与降钙素基因相关肽（CGRP）有关的单克隆抗体进行偏头痛的新型治疗]
Rinsho Shinkeigaku. 2020 Oct 24;60(10):668-676. doi: 10.5692/clinicalneurol.cn-001469. Epub 2020 Sep 5.
引用本文的文献
1
Efficacy and Safety of Switching between Anti-CGRP Monoclonal Antibodies: A Detailed Monthly and Long-term Follow-up Study and Literature Review.抗降钙素基因相关肽单克隆抗体之间转换的疗效与安全性：一项详细的月度及长期随访研究与文献综述
Intern Med. 2025 Jul 15;64(14):2114-2123. doi: 10.2169/internalmedicine.4360-24. Epub 2025 Jan 3.
2
Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study.降钙素基因相关肽单克隆抗体治疗偏头痛转换策略的有效性：一项回顾性队列研究。
Headache. 2025 Apr;65(4):619-630. doi: 10.1111/head.14865. Epub 2024 Dec 27.
3
[Complete remission of a migraine after treatment with cisplatin].[顺铂治疗后偏头痛完全缓解]
Rev Neurol. 2023 Jun 1;76(11):375. doi: 10.33588/rn.7611.2023096.
本文引用的文献
1
[Failure of an anti-CGRP monoclonal antibody in the treatment of migraine. Is it worthwhile trying another one?].[一种抗降钙素基因相关肽单克隆抗体治疗偏头痛失败。尝试另一种是否值得？]
Rev Neurol. 2022 Aug 16;75(4):87-91. doi: 10.33588/rn.7504.2021526.
2
Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.偏头痛对降钙素基因相关肽受体抗体治疗无应答者抗体转换的影响：一项多中心回顾性队列研究。
Cephalalgia. 2022 Apr;42(4-5):291-301. doi: 10.1177/03331024211048765. Epub 2021 Oct 13.
3
Early Experiences in Switching between Monoclonal Antibodies in Patients with Nonresponsive Migraine in Spain: A Case Series.西班牙非应答型偏头痛患者在单抗药物间转换的早期经验：一项病例系列研究。
Eur Neurol. 2022;85(2):132-135. doi: 10.1159/000518899. Epub 2021 Sep 10.
4
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.在 FOCUS 三期研究中，接受为期 6 个月的 fremanezumab 治疗后，患者的生活质量和工作效率得到改善，这些患者在接受 2 至 4 种偏头痛预防药物治疗后反应不足，为发作性和慢性偏头痛。
Headache. 2021 Oct;61(9):1376-1386. doi: 10.1111/head.14196. Epub 2021 Aug 10.
5
Failure to monoclonal antibodies against CGRP or its receptor does not preclude lack of efficacy to other drugs from the same therapeutic class.
Neurologia (Engl Ed). 2020 Nov 8. doi: 10.1016/j.nrl.2020.10.009.
6
Non-Responders to Treatment With Antibodies to the CGRP-Receptor May Profit From a Switch of Antibody Class.对降钙素基因相关肽受体抗体治疗无反应者可能会从抗体类型的转换中获益。
Headache. 2020 Feb;60(2):469-470. doi: 10.1111/head.13729. Epub 2019 Dec 24.
Zotero 插件